profit from every $100 of sales.
$0$100
Assertio Holdings
We have no price for Assertio Holdings since 29 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$23.50+0.00% today
+76.4% since Oct 8, 25
1-year low $9.071-year high $23.50
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Assertio Holdings sold, what it kept, and what it did with the cash.
Sales went from $156 million in 2022 to $119 million in 2025, with -$30.4 million of profit last year.
SalesProfit
Assertio Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Assertio Holdings | No profit yet | ||
 Merck KGaA | 25.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Assertio Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 156 | 152 | 125 | 119 | |
| 137 | 125 | 86 | 83 | |
| 58 | 16 | -19 | -17 | |
| 72 | -223 | 7 | 3 | |
| 110 | -332 | -22 | -30 | |
| 30.45 | -70.05 | -3.45 | -4.74 | |
| 88.0% | 82.2% | 68.6% | 70.2% | |
| 37.2% | 10.5% | -15.0% | -14.5% | |
| 70.2% | -218.3% | -17.3% | -25.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 414 | 286 | 285 | 267 |
| Cash | 65 | 73 | 51 | 10 |
| Total debt | 67 | 40 | 40 | 40 |
| Total liabilities | 188 | 148 | 164 | 173 |
| 226 | 138 | 121 | 94 | |
| 4 | 5 | 6 | 6 | |
| 10.5% | -111.7% | -9.3% | -16.1% | |
| 48.6% | -240.5% | -17.8% | -32.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 79 | 50 | 26 | -28 | |
| 0 | 1 | – | – | |
| 78 | 49 | 26 | -28 | |
| Dividends paid | – | – | – | – |
| 1 | 8 | 0 | 0 | |
| 8 | 9 | 5 | 3 |
Valuation
- –
- –
- –
- 1.9×
- 1.3×
- –
- 68.2×
- -18.6%
- -20.0%
- 0.0%
Profitability
- 70.2%
- -14.5%
- -25.6%
- -2.3%
- -20.2%
- -37.1%
- -37.7%
- -16.4%
- -20.2%
- 1.7%
Growth
- −8.7%
- –
- −206.7%
- –
- +22.1%
Financial health
- 11.2×
- 0.52
- 18.6%
- -14.7×
- 1.82
- 1.57
- 0.48
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 958
Bottom 13%of 888
Bottom 8%of 889
Bottom 4%of 987
What analysts expect
- Average price target
- $18.00
- Range
- $18.00 – $18.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -2.93 | -1.91 | −53.4% |
| Mar 16, 2026 | -1.86 | -3.05 | +39.0% |
| Nov 10, 2025 | 1.65 | -1.20 | +237.5% |
| Aug 11, 2025 | -0.17 | -0.10 | −70.0% |
| May 12, 2025 | -0.14 | -0.06 | −133.3% |
| Mar 12, 2025 | -0.11 | -0.05 | −120.0% |
| Nov 11, 2024 | -0.03 | -0.05 | +40.0% |
| Aug 7, 2024 | -0.04 | -0.03 | −25.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
42No pass
Philip Fisher
37No pass
Peter Lynch
24No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
30No pass
Questions about Assertio Holdings
Is Assertio Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Assertio Holdings AI analysis
What does Assertio Holdings do?
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. It is in Drug Manufacturers - Specialty & Generic.
Does Assertio Holdings pay a dividend?
No. Assertio Holdings does not pay a dividend at the moment; in 2025 it returned $189,000 to shareholders by buying back its own shares.
Is Assertio Holdings stock halal?
No. Assertio Holdings does not pass our halal screen: its cash and receivables are 86% of its market value, at or above the 49% limit. How we check
Who are Assertio Holdings's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Assertio Holdings's.
Prices: daily closes to Jun 29, 2026. Fundamentals: company reports via invest-like data.